Table 2.
Multivariable (MV) models of the association between baseline factors and macular ganglion cell-inner plexiform layer (mGCIPL) thickness.
| mGCIPL thickness | Thin mGCIPL | |||
|---|---|---|---|---|
| MV model | Sensitivity Analysisa | MV model | Sensitivity Analysisa | |
| β (95% CI) | OR (95% CI) | |||
| Age (per 5 years) | −1.07 (−1.28 to −0.86) | −0.95 (−1.17 to −0.74) | 1.38 (1.24-1.53) | 1.38 (1.24-1.54) |
| Male sex | −0.06 (−0.82 to 0.71) | 0.09 (−0.70 to 0.89) | 1.30 (0.93-1.81) | 1.24 (0.87-1.76) |
| Alcohol consumption (g/week) | ||||
| 0 | −0.87 (−2.25 to 0.52) | −0.61 (−2.02 to 0.81) | 1.40 (0.89-2.20) | 1.87 (1.14-3.07) |
| 15-74 | 0.10 (−0.76 to 0.97) | −0.47 (−1.36 to 0.43) | 1.05 (0.70-1.58) | 1.34 (0.88-2.03) |
| 75-140 | −1.09 (−2.29 to 0.11) | −1.63 (−2.92 to −0.34) | 0.93 (0.54-1.60) | 1.41 (0.81-2.46) |
| >140 | −1.44 (−2.72 to −0.16) | −1.69 (−3.01 to −0.38) | 1.08 (0.64-1.81) | 1.53 (0.90-2.60) |
| Diabetes | −2.10 (−4.25 to 0.05) | −2.22 (−4.92 to 0.48) | 1.89 (1.09-3.27) | 1.81 (0.90-3.63) |
| Myopia | −2.55 (−3.17 to −1.94) | −2.48 (−3.15 to −1.80) | 2.11 (1.63-2.73) | 2.55 (1.89-3.44) |
| Hyperopia | −0.07 (−1.02 to 0.89) | −0.34 (−1.46 to 0.77) | 0.90 (0.63-1.28) | 0.95 (0.63-1.43) |
| Cataract | 1.21 (0.89-1.66) | |||
| Glaucoma | −1.74 (−2.77 to −0.70) | 1.49 (0.98-2.28) | ||
| IL-6 (natural log) | −0.56 (−1.11 to −0.01) | −0.73 (−1.32 to −0.13) | 1.24 (0.97-1.59) | 1.32 (1.01-1.73) |
| Long-term sVCAM | ||||
| Increasingb | −0.21 (−1.08 to 0.65) | −0.22 (−1.10 to 0.66) | ||
| Highc | −0.85 (−1.72 to 0.03) | −0.78 (−1.67 to 0.11) | ||
| Long-term hsCRP | ||||
| Increasingb | 1.46 (1.01-2.11) | 1.31 (0.88-1.93) | ||
| Highc | 1.74 (1.14-2.65) | 1.66 (1.06-2.56) | ||
CI=confidence interval, OR=Odds Ratio, IL-6=interleukin-6, sVCAM=soluble vascular adhesion, hsCRP=high-sensitivity C-reactive protein
a
Excluding those with age-related macular degeneration, diabetic retinopathy, glaucoma, or cataract
b
Biomarker level increased by 1 or more tertiles from baseline examination to the 5-year follow-up examination
c
Biomarker level in highest tertile at baseline examination and at 5-year follow-up examination